Overview:

Summary

Global Markets Direct’s, 'Mixed Dyslipidemia - Pipeline Review, Q2 2011', provides an overview of the Mixed Dyslipidemia therapeutic pipeline. This report provides information on the therapeutic development for Mixed Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mixed Dyslipidemia. 'Mixed Dyslipidemia - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Mixed Dyslipidemia.
- A review of the Mixed Dyslipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mixed Dyslipidemia pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Mixed Dyslipidemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus of Mixed Dyslipidemia therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Mixed Dyslipidemia Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Mixed Dyslipidemia 6
Mixed Dyslipidemia Therapeutics under Development by Companies 8
Late Stage Products 9
Comparative Analysis 9
Pre-Clinical Stage Products 10
Comparative Analysis 10
Mixed Dyslipidemia Therapeutics - Products under Development by Companies 11
Companies Involved in Mixed Dyslipidemia Therapeutics Development 12
Abbott Laboratories 12
Merck & Co., Inc. 12
Mixed Dyslipidemia - Therapeutics Assessment 13
Assessment by Monotherapy Products 13
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Late Stage Drug Profiles 18
MK-0524A - Drug Profile 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
MK-0524B - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Certriad - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
NanoActive Rosuvastatin - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Mixed Dyslipidemia Therapeutics – Drug Profile Updates 24
Mixed Dyslipidemia Therapeutics - Discontinued Products 25
Mixed Dyslipidemia - Featured News 26
Apr 18, 2011: Amarin's AMR101 Phase III ANCHOR Trial Meets All Primary And Secondary Endpoints 26
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 29
Contact Us 29
Disclaimer 29"

List of Tables
Number of Products Under Development for Mixed Dyslipidemia, Q2 2011 6
Products under Development for Mixed Dyslipidemia – Comparative Analysis, Q2 2011 7
Number of Products under Development by Companies, Q2 2011 8
Comparative Analysis by Late Stage Development, Q2 2011 9
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011 10
Products under Development by Companies, Q2 2011 11
Abbott Laboratories, 2011 12
Merck & Co., Inc., 2011 12
Assessment by Monotherapy Products, Q2 2011 13
Assessment by Stage and Route of Administration, Q2 2011 15
Assessment by Molecule Type, Q2 2011 17
Mixed Dyslipidemia Therapeutics – Drug Profile Updates 24
Discontinued Products 25"

List of Figures
Number of Products under Development for Mixed Dyslipidemia, Q2 2011 6
Products under Development for Mixed Dyslipidemia – Comparative Analysis, Q2 2011 7
Products under Development by Companies, Q2 2011 8
Late Stage Products, Q2 2011 9
Pre-Clinical Stage Products, Q2 2011 10
Assessment by Monotherapy Products, Q2 2011 13
Assessment by Route of Administration, Q2 2011 14
Assessment by Stage and Route of Administration, Q2 2011 15
Assessment by Molecule Type, Q2 2011 16
Assessment by Stage and Molecule Type, Q2 2011 17